<DOC>
	<DOCNO>NCT01023659</DOCNO>
	<brief_summary>Bupropion varenicline indicate smoke cessation . The objective study two-fold : ( 1 ) explore logistic feasibility distribute bupropion varenicline free charge treatment-seeking smoker province Ontario , Canada ( 2 ) evaluate real-world effectiveness bupropion varenicline treatment Ontario compare no-drug comparison group . In open label study , Ontario smokers smoke 10 cigarette per day intend quit smoke next 30 day , enroll via study website , visit physician receive prescription bupropion varenicline 12 week neither choose , form no-drug comparison group . All participant receive weekly motivational email 12 week . Abstinence measure take 4 , 8 12 week 6 12 month . The proportion eligible participant able confirm appointment physician receive prescription also measure .</brief_summary>
	<brief_title>Distribution Bupropion Varenicline Increase Smoking Cessation Attempts</brief_title>
	<detailed_description>Bupropion varenicline effective pharmacotherapies smoke cessation , population level impact limited combination factor . Both bupropion varenicline available prescription , however smoke cessation clinic number 25 % smoker receive information smoking cessation aid healthcare provider . Mass distribution approach , bypass clinic physician , successful nicotine replacement therapy many jurisdiction , include Ontario . However , bupropion varenicline potential make great impact give superior result clinical trial . Bupropion varenicline present unique challenge prescribe medication , therefore propose variant mass distribution method test whether practical distribute large number people expansive geographic area ( i.e. , Ontario ) . We hypothesize engage smoker opportunity receive free bupropion varenicline , initiate appointment physician obtain prescription would fill mailed smoker central pharmacy would logistically feasible approach reach high number smoker wide geographic area . Our second hypothesis consistent result clinical study , general population varenicline would associate high abstinence rate bupropion , varenicline bupropion group would achieve high abstinence rate make quit attempt without pharmacotherapy aid . This open label , proof-of-concept study , wherein 2000 eligible participant opportunity receive bupropion ( Zyban® ) varenicline ( Champix® ) 12 week conjunction weekly motivational email . Eligible participant discuss doctor two medication appropriate use smoke cessation aid . It also possible participant his/her doctor may decide pursue smoke cessation use either medication . These participant form third intervention group , receive weekly motivational email . All participant set quit date choosing , receive medication set quit date 7 day start medication . The participant enroll study via study 's website , time read consent form , answer eligibility question complete baseline questionnaire . Data relate outcome measure adverse event collect 4 , 8 12 week start treatment 6 12 month end treatment .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>male female , least 18 year age , resident Ontario , smoke least 10 cigarette per day , smoke daily least past 3 month , smoke least 100 cigarette lifetime intend quit smoke next 30 day . history brain injury seizure ( ) ; pregnancy , lactation risk become pregnant ; allergy sensitivity bupropion varenicline ; current use monoamine oxidase inhibitor ( MAOIs ) , thioridazine , varenlicine buproprion ; severe liver impairment ; history anorexia /or bulimina .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Smoking cessation</keyword>
	<keyword>Bupropion</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Population-level</keyword>
	<keyword>Mass distribution</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>